Compare Charles River Laboratories Intl. Inc (CRL) vs EPAM Systems Inc (EPAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs EPAM Systems Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $286.31 (market cap $13.46B), while EPAM Systems Inc trades at $99 (market cap $5.15B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.6× EPAM Systems Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.
| CRL | EPAM | |
|---|---|---|
Market Cap | $13.46B | $5.15B |
Sector | Health | Technology |
52-Week High | $282.00 | $221.40 |
52-Week Low | $145.57 | $76.04 |
Enterprise Value | $16.30B | $4.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
EPAM Systems trades at $99.00, up 1.67% today, with a bearish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with a P/E of 13.55 and P/S of 0.97, while profitability remains solid with a net margin of 7.15%. Recent news highlights strong Q2 2026 earnings but a lowered revenue outlook due to slower North American growth and a new OpenAI partnership.
Outlook is mixed: strong fundamentals and analyst consensus ($117.27 target) support upside, but technical weakness and growth headwinds pose risks. Investment opportunity lies in valuation discount and AI initiatives, countered by demand volatility and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →
